BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C, Bousquet C. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A 2003;100:155-60. [PMID: 12490654 DOI: 10.1073/pnas.0136771100] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Gailhouste L, Liew LC, Hatada I, Nakagama H, Ochiya T. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death Dis 2018;9:468. [PMID: 29700299 DOI: 10.1038/s41419-018-0487-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
2 Tao Z, Suo H, Zhang L, Jin Z, Wang Z, Wang D, Wu M, Peng N, Zhao Y, Chen B. MRPL13 is a Prognostic Cancer Biomarker and Correlates with Immune Infiltrates in Breast Cancer. Onco Targets Ther 2020;13:12255-68. [PMID: 33273831 DOI: 10.2147/OTT.S263998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kerros C, Cavey T, Sola B, Jauzac P, Allouche S. Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells. J Exp Clin Cancer Res 2009;28:77. [PMID: 19500423 DOI: 10.1186/1756-9966-28-77] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Barbieri F, Pattarozzi A, Gatti M, Porcile C, Bajetto A, Ferrari A, Culler MD, Florio T. Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology 2008;149:4736-46. [PMID: 18566118 DOI: 10.1210/en.2007-1762] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
5 Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 2021;13:5117. [PMID: 34680266 DOI: 10.3390/cancers13205117] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Minn AH, Pise-masison CA, Radonovich M, Brady JN, Wang P, Kendziorski C, Shalev A. Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. Biochemical and Biophysical Research Communications 2005;336:770-8. [DOI: 10.1016/j.bbrc.2005.08.161] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
7 Thibault B, Ramos-Delgado F, Pons-Tostivint E, Therville N, Cintas C, Arcucci S, Cassant-Sourdy S, Reyes-Castellanos G, Tosolini M, Villard AV, Cayron C, Baer R, Bertrand-Michel J, Pagan D, Ferreira Da Mota D, Yan H, Falcomatà C, Muscari F, Bournet B, Delord JP, Aksoy E, Carrier A, Cordelier P, Saur D, Basset C, Guillermet-Guibert J. Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. EMBO Mol Med 2021;13:e13502. [PMID: 34033220 DOI: 10.15252/emmm.202013502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rinke A, Krug S. Neuroendocrine tumours – Medical therapy: Biological. Best Practice & Research Clinical Endocrinology & Metabolism 2016;30:79-91. [DOI: 10.1016/j.beem.2015.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
9 Li M, Wang X, Li W, Li F, Yang H, Wang H, Brunicardi FC, Chen C, Yao Q, Fisher WE. Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer. Cancer Sci. 2008;99:2218-2223. [PMID: 18823376 DOI: 10.1111/j.1349-7006.2008.00940.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
10 Cordelier P, Buscail L. La thérapie génique : une réalité pour demain ? Gastroentérologie Clinique et Biologique 2005;29:724-31. [DOI: 10.1016/s0399-8320(05)82162-1] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
11 Qin RY, Fang RL, Gupta MK, Liu ZR, Wang DY, Chang Q, Chen YB. Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis. World J Gastroenterol 2004; 10(1): 132-135 [PMID: 14695784 DOI: 10.3748/wjg.v10.i1.132] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
12 Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways. J Cell Mol Med 2010;14:2570-84. [PMID: 20629989 DOI: 10.1111/j.1582-4934.2010.01125.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
13 Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, Baroni MG. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res 2006;65:120-5. [PMID: 16479142 DOI: 10.1159/000091408] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
14 Stumm RK, Zhou C, Schulz S, Endres M, Kronenberg G, Allen JP, Tulipano G, Höllt V. Somatostatin receptor 2 is activated in cortical neurons and contributes to neurodegeneration after focal ischemia. J Neurosci 2004;24:11404-15. [PMID: 15601946 DOI: 10.1523/JNEUROSCI.3834-04.2004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
15 Öberg K. Somatostatin analog octreotide LAR ® in gastro–entero–pancreatic tumors. Expert Review of Anticancer Therapy 2014;9:557-66. [DOI: 10.1586/era.09.26] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
16 Santamaría B, Benito-Martin A, Ucero AC, Aroeira LS, Reyero A, Vicent MJ, Orzáez M, Celdrán A, Esteban J, Selgas R, Ruíz-Ortega M, Cabrera ML, Egido J, Pérez-Payá E, Ortiz A. A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. PLoS One 2009;4:e6634. [PMID: 19675677 DOI: 10.1371/journal.pone.0006634] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
17 Abdel-Hamid NM, Mohafez OM, Nazmy MH, Farhan A, Thabet K. The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma. Environ Health Prev Med 2015;20:195-203. [PMID: 25726025 DOI: 10.1007/s12199-015-0451-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286:230-237. [PMID: 18359151 DOI: 10.1016/j.mce.2008.02.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 8.0] [Reference Citation Analysis]
19 Leu FP, Nandi M. GPCR somatostatin receptor extracellular loop 2 is a key ectodomain for making subtype-selective antibodies with agonist-like activities in the pancreatic neuroendocrine tumor BON cell line. Pancreas 2010;39:1155-66. [PMID: 20531241 DOI: 10.1097/MPA.0b013e3181de8c05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Santamaría B, Ucero AC, Reyero A, Selgas R, Ruiz-Ortega M, Catalán M, Egido J, Ortiz A. 3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization. Nephrol Dial Transplant 2008;23:3307-15. [PMID: 18524790 DOI: 10.1093/ndt/gfn273] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
22 Najib S, Saint-Laurent N, Estève JP, Schulz S, Boutet-Robinet E, Fourmy D, Lättig J, Mollereau C, Pyronnet S, Susini C, Bousquet C. A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway. Mol Cell Biol 2012;32:1004-16. [PMID: 22203038 DOI: 10.1128/MCB.06252-11] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
23 Lee JT, Lee T, Kim C, Kim N, Kwon TK. Over-expression of Reticulon 3 (RTN3) enhances TRAIL-mediated apoptosis via up-regulation of death receptor 5 (DR5) and down-regulation of c-FLIP. Cancer Letters 2009;279:185-92. [DOI: 10.1016/j.canlet.2009.01.035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
24 Hernández-Pinto AM, Puebla-Jiménez L, Arilla-Ferreiro E. alpha-Tocopherol decreases the somatostatin receptor-effector system and increases the cyclic AMP/cyclic AMP response element binding protein pathway in the rat dentate gyrus. Neuroscience 2009;162:106-17. [PMID: 19393293 DOI: 10.1016/j.neuroscience.2009.04.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
25 Baer R, Cintas C, Therville N, Guillermet-Guibert J. Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter? Adv Biol Regul. 2015;59:19-35. [PMID: 26166735 DOI: 10.1016/j.jbior.2015.05.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
26 Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci. 2004;1014:121-131. [PMID: 15153426 DOI: 10.1196/annals.1294.012] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
27 Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin - active participant or bystander in gastric carcinogenesis? Nat Rev Cancer. 2006;6:936-946. [PMID: 17128210 DOI: 10.1038/nrc2014] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 6.6] [Reference Citation Analysis]
28 Li M, Li W, Kim HJ, Yao Q, Chen C, Fisher WE. Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. Journal of Surgical Research 2004;119:130-7. [DOI: 10.1016/j.jss.2004.03.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
29 War SA, Kim B, Kumar U. Human somatostatin receptor-3 distinctively induces apoptosis in MCF-7 and cell cycle arrest in MDA-MB-231 breast cancer cells. Molecular and Cellular Endocrinology 2015;413:129-44. [DOI: 10.1016/j.mce.2015.06.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
30 Wu P, Mao JD, Yan JY, Rui J, Zhao YC, Li XH, Xu GQ. Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer. World J Gastroenterol 2005;11:7211-7. [PMID: 16437675 DOI: 10.3748/wjg.v11.i45.7211] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
31 Costanzi E, Simioni C, Conti I, Laface I, Varano G, Brenna C, Neri LM. Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives. J Cell Physiol 2021;236:2505-18. [PMID: 32989768 DOI: 10.1002/jcp.30062] [Reference Citation Analysis]
32 Cordelier P, Bienvenu C, Lulka H, Marrache F, Bouisson M, Openheim A, Strayer DS, Vaysse N, Pradayrol L, Buscail L. Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. Cancer Gene Ther 2007;14:19-29. [PMID: 16990845 DOI: 10.1038/sj.cgt.7700987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
33 Castillo V, Theodoropoulou M, Stalla J, Gallelli MF, Cabrera-blatter MF, Haedo MR, Labeur M, Schmid HA, Stalla GK, Arzt E. Effect of SOM230 (Pasireotide) on Corticotropic Cells: Action in Dogs with Cushing’s Disease. Neuroendocrinology 2011;94:124-36. [DOI: 10.1159/000327429] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
34 Mastrodimou N, Lambrou GN, Thermos K. Effect of somatostatin analogues on chemically induced ischaemia in the rat retina. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:44-53. [PMID: 15645293 DOI: 10.1007/s00210-004-1011-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
35 Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 2011; 17(3): 313-321 [PMID: 21253389 DOI: 10.3748/wjg.v17.i3.313] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
36 Rivera JA, Alturaihi H, Kumar U. Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J Carcinog 2005;4:10. [PMID: 16018813 DOI: 10.1186/1477-3163-4-10] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
37 Yang LQ, Fang DC, Wang RQ, Yang SM. Effect of NF-κB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 2004; 10(1): 22-25 [PMID: 14695762 DOI: 10.3748/wjg.v10.i1.22] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
38 Yang SK, Parkington HC, Epelbaum J, Keating DJ, Chen C. Somatostatin decreases voltage-gated Ca2+ currents in GH3 cells through activation of somatostatin receptor 2. Am J Physiol Endocrinol Metab 2007;292:E1863-70. [PMID: 17327372 DOI: 10.1152/ajpendo.00047.2007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
39 Liu ZR, Qin RY, Wu GS, Chang Q, Wang DY, Zou SQ, Qiu FZ. Effect of octreotide on human pancreatic cancer cells after transfected with somatostatin receptor type 2 gene. World J Gastroenterol 2004; 10(15): 2292-2294 [PMID: 15259086 DOI: 10.3748/wjg.v10.i15.2292] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, Whitt J, Carter AM, Markert JM, Bibb JA, Chen H, Zhou L, Jaskula-Sztul R, Liu XM. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Ther 2021;28:799-812. [PMID: 32684623 DOI: 10.1038/s41417-020-0196-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
41 Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011;32:247-71. [PMID: 21123741 DOI: 10.1210/er.2010-0002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 148] [Article Influence: 15.0] [Reference Citation Analysis]
42 Guillermet-Guibert J, Lahlou H, Pyronnet S, Bousquet C, Susini C. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol 2005;19:535-51. [PMID: 16183526 DOI: 10.1016/j.bpg.2005.03.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
43 Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol. 2008;286:40-48. [PMID: 17913342 DOI: 10.1016/j.mce.2007.08.012] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
44 Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17:1733-1742. [PMID: 16801334 DOI: 10.1093/annonc/mdl105] [Cited by in Crossref: 194] [Cited by in F6Publishing: 167] [Article Influence: 12.9] [Reference Citation Analysis]
45 Guillermet-guibert J, Saint-laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C. Novel synergistic mechanism for sst2 somatostatin and TNFα receptors to induce apoptosis: crosstalk between NF-κB and JNK pathways. Cell Death Differ 2007;14:197-208. [DOI: 10.1038/sj.cdd.4401939] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
46 Casarini APM, Pinto EM, Jallad RS, Giorgi RR, Giannella-neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 2006;29:826-30. [DOI: 10.1007/bf03347378] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
47 Li M, Zhang R, Li F, Wang H, Kim HJ, Becnel L, Yao Q, Chen C, Fisher WE. Transfection of SSTR-1 and SSTR-2 inhibits Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue. J Am Coll Surg. 2005;201:571-578. [PMID: 16183496 DOI: 10.1016/j.jamcollsurg.2005.06.089] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
48 Buscail L, Bournet B, Vernejoul F, Cambois G, Lulka H, Hanoun N, Dufresne M, Meulle A, Vignolle-Vidoni A, Ligat L, Saint-Laurent N, Pont F, Dejean S, Gayral M, Martins F, Torrisani J, Barbey O, Gross F, Guimbaud R, Otal P, Lopez F, Tiraby G, Cordelier P. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. Mol Ther 2015;23:779-89. [PMID: 25586689 DOI: 10.1038/mt.2015.1] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
49 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 35.0] [Reference Citation Analysis]
50 Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncology 2011;7:895-913. [DOI: 10.2217/fon.11.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
51 Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, Cavallaro A, Beretta M, Alessandria I, Luca S, Motta M. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Archives of Gerontology and Geriatrics 2009;48:213-7. [DOI: 10.1016/j.archger.2008.01.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
52 Bousquet C, Guillermet J, Vernejoul F, Lahlou H, Buscail L, Susini C. Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis. 2004;36 Suppl 1:S2-S7. [PMID: 15077905 DOI: 10.1016/j.dld.2003.11.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
53 Wang JH, Xing QT, Yuan MB. Antineoplastic effects of octreotide on human gallbladder cancer cells in vitroWorld J Gastroenterol 2004; 10(7): 1043-1046 [PMID: 15052690 DOI: 10.3748/wjg.v10.i7.1043] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
54 Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-guibert J, Pyronnet S, Bousquet C. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends in Endocrinology & Metabolism 2014;25:115-27. [DOI: 10.1016/j.tem.2013.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
55 Kilian M, Gregor JI, Heukamp I, Helmecke K, Hanel M, Wassersleben B, Walz MK, Schimke I, Kristiansen G, Wenger FA. Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster. Clin Exp Metastasis 2009;26:719-27. [PMID: 19521786 DOI: 10.1007/s10585-009-9271-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
56 Quan ZW, Yang Y, Li JY, Gong W, Qin YY, Li SG. The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation. Biomed Pharmacother. 2010;64:451-457. [PMID: 20359855 DOI: 10.1016/j.biopha.2010.01.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
57 Lee TJ, Jang JH, Noh HJ, Park EJ, Choi KS, Kwon TK. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells. J Cell Biochem 2010;109:885-95. [PMID: 20127709 DOI: 10.1002/jcb.22504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.2] [Reference Citation Analysis]
58 Yang SK, Chen C. Involvement of somatostatin receptor subtypes in membrane ion channel modification by somatostatin in pituitary somatotropes. Clin Exp Pharmacol Physiol. 2007;34:1221-1227. [PMID: 17892506 DOI: 10.1111/j.1440-1681.2007.04806.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
59 Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999-1017. [PMID: 14654798 DOI: 10.1038/nrd1255] [Cited by in Crossref: 379] [Cited by in F6Publishing: 345] [Article Influence: 22.3] [Reference Citation Analysis]
60 Volante M, Rosas R, Allìa E, Granata R, Baragli A, Muccioli G, Papotti M. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol. 2008;286:219-229. [PMID: 18248880 DOI: 10.1016/j.mce.2007.12.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
61 Zalatnai A. Pancreatic cancer - a continuing challenge in oncology. Pathol Oncol Res 2003;9:252-63. [PMID: 14688834 DOI: 10.1007/BF02893388] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
62 Li M, Fisher WE, Kim HJ, Wang X, Brunicardi CF, Chen C, Yao Q. Somatostatin, Somatostatin Receptors, and Pancreatic Cancer. World J Surg 2005;29:293-6. [DOI: 10.1007/s00268-004-7814-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
63 Borbath I, Leclercq IA, Sempoux C, Abarca-quinones J, Desaeger C, Horsmans Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chemico-Biological Interactions 2010;183:238-48. [DOI: 10.1016/j.cbi.2009.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
64 Qiu CZ, Wang C, Huang ZX, Zhu SZ, Wu YY, Qiu JL. Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer. World J Gastroenterol 2006; 12(13): 2011-2015 [PMID: 16610049 DOI: 10.3748/wjg.v12.i13.2011] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
65 Wang CH, Tang CW, Liu CL, Tang LP. Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 2003; 9(9): 1904-1908 [PMID: 12970873 DOI: 10.3748/wjg.v9.i9.1904] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
66 Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncol Lett 2013;6:821-8. [PMID: 24137418 DOI: 10.3892/ol.2013.1435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
67 Mao JD, Wu P, Xia XH, Hu JQ, Huang WB, Xu GQ. Correlation between expression of gastrin, somatostatin and cell apoptosis regulation gene bcl-2/bax in large intestine carcinoma. World J Gastroenterol 2005; 11(5): 721-725 [PMID: 15655830 DOI: 10.3748/wjg.v11.i5.721] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
68 Owonikoko TK, Zhang G, Lallani SB, Chen Z, Martinson DE, Khuri FR, Lonial S, Marcus A, Sun SY. Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. PLoS One 2019;14:e0206309. [PMID: 30807575 DOI: 10.1371/journal.pone.0206309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Volante M, Bozzalla-Cassione F, Papotti M. Somato-statin receptors and their interest in diagnostic pathology. Endocr Pathol. 2004;15:275-291. [PMID: 15681851 DOI: 10.1385/EP:15:4:275] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
70 Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. Oncotarget 2017;8:104615-37. [PMID: 29262666 DOI: 10.18632/oncotarget.18403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
71 Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, Buscail L, Cordelier P. Characterization of the Bystander Effect of Somatostatin Receptor sst2 After In Vivo Gene Transfer into Human Pancreatic Cancer Cells. Human Gene Therapy 2005;16:1175-93. [DOI: 10.1089/hum.2005.16.1175] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
72 Dal Monte M, Petrucci C, Vasilaki A, Cervia D, Grouselle D, Epelbaum J, Kreienkamp HJ, Richter D, Hoyer D, Bagnoli P. Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. Neuropharmacology. 2003;45:1080-1092. [PMID: 14614951 DOI: 10.1016/s0028-3908(03)00296-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
73 Serrano-Fernández P, Ibrahim SM, Zettl UK, Thiesen HJ, Gödde R, Epplen JT, Möller S. Intergenomic consensus in multifactorial inheritance loci: the case of multiple sclerosis. Genes Immun 2004;5:615-20. [PMID: 15573086 DOI: 10.1038/sj.gene.6364134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
74 Xing Z, Zhou Z, Yu R, Li S, Li C, Nilsson S, Liu Z. XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells. J Exp Clin Cancer Res 2010;29:162. [PMID: 21143993 DOI: 10.1186/1756-9966-29-162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
75 Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013;34:228-52. [PMID: 23872332 DOI: 10.1016/j.yfrne.2013.07.005] [Cited by in Crossref: 170] [Cited by in F6Publishing: 148] [Article Influence: 21.3] [Reference Citation Analysis]
76 Mao JD, Wu P, Yang YL, Wu J, Huang H. Relationship between expression of gastrin, somatostatin, Fas/FasL and caspases in large intestinal carcinoma. World J Gastroenterol 2008; 14(18): 2802-2809 [PMID: 18473402 DOI: 10.3748/wjg.14.2802] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
77 Bousquet C, Guillermet-Guibert J, Saint-Laurent N, Archer-Lahlou E, Lopez F, Fanjul M, Ferrand A, Fourmy D, Pichereaux C, Monsarrat B, Pradayrol L, Estève JP, Susini C. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J 2006;25:3943-54. [PMID: 16917505 DOI: 10.1038/sj.emboj.7601279] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
78 Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295. [PMID: 23476673 DOI: 10.1155/2013/926295] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
79 Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53:1180-1189. [PMID: 15247189 DOI: 10.1136/gut.2003.036053] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 4.3] [Reference Citation Analysis]
80 Kumar U, Grant M. Somatostatin and somatostatin receptors. Results Probl Cell Differ 2010;50:137-84. [PMID: 19859675 DOI: 10.1007/400_2009_29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 28] [Article Influence: 0.9] [Reference Citation Analysis]
81 陈滟珊, 王承党. 生长抑素对消化道肿瘤的调控作用. 世界华人消化杂志 2004; 12(1): 184-189 [DOI: 10.11569/wcjd.v12.i1.184] [Reference Citation Analysis]
82 Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, Le Guellec S, Delisle MB, Schally AV, Susini C, Pyronnet S, Bousquet C. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci U S A 2009;106:17769-74. [PMID: 19805200 DOI: 10.1073/pnas.0908674106] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
83 Cives M, Strosberg J. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. Drugs 2015;75:847-58. [DOI: 10.1007/s40265-015-0397-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]